Keyphrases
Breast Cancer
100%
Overall Survival
78%
Human Epidermal Growth Factor Receptor 2 (HER2)
67%
Median Progression-free Survival
44%
Progression-free Survival
41%
Metastatic Breast Cancer
41%
Trastuzumab
41%
Median Overall Survival
36%
Metastatic Triple-negative Breast Cancer
33%
Normal Breast
33%
Advanced Triple-negative Breast Cancer
33%
Capecitabine Monotherapy
33%
Treatment Regimen
33%
Genomic Studies
33%
Copenhagen
33%
Third-line Treatment
33%
Breast Cancer Diagnosis
33%
Breast Cancer Genomics
33%
Advanced Breast Cancer
33%
Molecular Subtypes
33%
Confidence Interval
33%
Dual Blockade
33%
HER2-positive Metastatic Breast Cancer
33%
Biosimilar
33%
Brain Development
33%
Brain Metastases
33%
Population-based
33%
Capecitabine
30%
Pertuzumab
30%
Treatment Line
27%
High Risk
25%
Survival Median
22%
Triple-negative Breast Cancer
22%
Primary Diagnosis
16%
Denmark
16%
High Tumor Burden
16%
ER-negative
16%
Oncology Department
13%
Chemotherapy
13%
Basal-like
13%
Luminal Breast Cancer
13%
Locally Recurrent
11%
Real-word Study
8%
Inclusion Criteria
8%
Estrogen Receptor-negative
8%
Human Epidermal Growth Factor Receptor
8%
Female Patients
8%
Estrogen Receptor-positive
8%
Targeted Therapy
8%
Alternative Chemotherapy
8%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
73%
Metastatic Breast Cancer
67%
Overall Survival
65%
Progression Free Survival
63%
Trastuzumab
40%
Retrospective Study
39%
Gamma Urogastrone
39%
Capecitabine
33%
Monotherapy
33%
Epidermal Growth Factor Receptor 2
33%
Biosimilar Agent
33%
Pertuzumab
29%
Brain Metastasis
26%
Neoplasm
13%
Disease
12%
Chemotherapy
11%
Estrogen Receptor
11%
First-Line Chemotherapy
6%
Cancer Growth
6%
Vinorelbine
6%
Recurrent Disease
5%
Epidermal Growth Factor Receptor
5%
Population Study
5%
Medicine and Dentistry
Breast Cancer
75%
Capecitabine
36%
Cancer Diagnosis
33%
Retrospective Study
33%
Triple Negative Breast Cancer
33%
Overall Survival
33%
Monotherapy
33%
Progression Free Survival
30%
Oncology
11%
Estrogen Receptor
11%
Disease
9%
Targeted Therapy
5%
Epidermal Growth Factor Receptor
5%
Gamma Urogastrone
5%
